Clinical trials: psoriasis
Plaque Psoriasis
Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis
This is an open-label, safety study designed to assess the multiple-dose pharmacokinetics and potential for adrenal suppression following topical treatment with halobetasol propionate 0.05% spray applied twice-daily in adult…
- Trial name
- NCT03298581
- Testing
- Halobetasol Propionate
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis
This is a study to evaluate pharmacokinetics (PK), safety and tolerability of ABBV-157 in healthy volunteers and in participants with chronic plaque psoriasis, and to evaluate the efficacy of ABBV-157 in the participants with…
- Trial name
- NCT03922607
- Testing
- ABBV-157
- Where
- 10 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- AbbVie
Psoriasis
An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants
This is an investigational study of Cyclosporine on the experimental medication BMS-986165 in healthy male participants.
- Trial name
- NCT03419910
- Testing
- BMS-986165, Cyclosporine
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis
Study B7451005 is a Phase 2 study which will assess the efficacy and safety of PF-04965842 in patients with moderate to severe psoriasis.
- Trial name
- NCT02201524
- Testing
- PF-04965842
- Where
- 45 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- Pfizer
Moderate to Severe Plaque Psoriasis
Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate ICP-488.Efficacy, safety, PK, and PD characteristics in Chinese adults with moderate to severe plaque psoriasis.
- Trial name
- NCT06109818
- Testing
- ICP-488 Tablets
- Where
- 31 sites in China
- Volunteers
- 129 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Psoriasis
A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis
The purpose of this study is to evaluate the safety and how the body affects a drug (CNTO 1959) in healthy volunteers and in patients with psoriasis.
- Trial name
- NCT00925574
- Where
- 8 sites in United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Ankylosing Spondylitis, Psoriatic Arthritis
Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium
This observational study will document to what extent in daily clinical practice the work productivity is affected before and after the start of adalimumab treatment.
- Trial name
- SPACTIVE (NCT01845818)
- Volunteers
- 183 people
- Sponsor
- AbbVie
Moderate to Severe Palmoplantar Psoriasis
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis
Purpose of the study was to demonstrate the efficacy of secukinumab versus placebo on palmoplantar psoriasis and to assess the long term efficacy, safety and tolerability of secukinumab.
- Trial name
- GESTURE (NCT01806597)
- Testing
- secukinumab 150 mg, secukinumab 300 mg
- Where
- 54 sites in United States, Australia and 13 more
- Volunteers
- 205 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
This is a randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the efficacy and safety of HB0017 in subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT05531682
- Testing
- HB0017
- Where
- 21 sites in China
- Volunteers
- 160 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Parapsoriasis, Healthy Volunteers
Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis
To evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of CC-90005 in healthy subjects and subjects with moderate to severe plaque-type psoriasis.
- Trial name
- NCT02502188
- Testing
- CC-90005
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Celgene
Scalp Psoriasis
Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis
The purpose of this study is to compare the clinical efficacy of once daily treatment for 4 weeks with Xamiol® gel (calcipotriol plus betamethasone) with twice daily treatment for 4 weeks with Calcipotriol Scalp Solution in…
- Trial name
- NCT01195831
- Testing
- Xamiol® gel, Calcipotriol scalp solution
- Where
- 9 sites in China
- Volunteers
- 244 people
- Sponsor
- LEO Pharma
Psoriasis
BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test
To explore the efficacy and safety of four BAY1003803 formulations by means of a within subject comparison in an open Psoriasis Plaque Test
- Trial name
- NCT02940002
- Testing
- BAY1003803, Clobetasol propionate, Betamethasone/calcipotriene
- Where
- 3 sites in Germany
- Volunteers
- 23 people
- Sponsor
- Bayer
Psoriasis Vulgaris
Efficacy and Safety of Novel Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis
This was a Phase I, single-center, randomized, controlled trial to evaluate the antipsoriatic efficacy of calcipotriol in novel formulations based on AKVANO technology as compared to marketed calcipotriol products (Daivonex®…
- Trial name
- AKVANO-AKP01 (NCT05488990)
- Testing
- AKVANO-Calcipotriol formulation 1, AKVANO-Calcipotriol formulation 2, AKVANO vehicle formulation 1
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Lipidor AB
Psoriasis
Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis
This study is to evaluate the efficacy and safety for long term use of M518101 in subjects with plaque psoriasis.
- Trial name
- NCT01908595
- Testing
- M518101
- Where
- 31 sites in United States
- Volunteers
- 480 people
- Sponsor
- Maruho North America Inc.
Plaque Psoriasis
Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis
The purpose of this study is to determine whether the investigational lotion is an effective treatment of moderate to severe plaque psoriasis in comparison to an approved cream.
- Trial name
- NCT01166646
- Testing
- Halobetasol Proprionate Lotion 0.05%, Halobetasol Proprionate Cream 0.05%
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- Therapeutics, Inc.
Psoriatic Arthritis, Spondyloarthritis, Axial
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with Active Psoriatic Arthritis (UP-SPOUT)
- Trial name
- UP-SPOUT (NCT06454188)
- Testing
- Upadacitinib 15 MG [Rinvoq]
- Where
- 5 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- CARE ARTHRITIS LTD.
Psoriasis
A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
This is a Phase 4 multicenter, uncontrolled open-label study design. There will be a total of 10 study visits at Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Week 28, Week 40, Week 52 and Week 64, with subjects…
- Trial name
- NCT03718299
- Testing
- Injections of tildrakizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Plaque Psoriasis
A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation
The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the…
- Trial name
- NCT02310750
- Testing
- PF-06700841 oral solution/suspension, PF-06700841 tablet
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Pfizer
Plaque Psoriasis
Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis
The purpose of this study is to compare the safety and efficacy profiles of Tazarotene Cream, 0.05% and Tazorac® (Tazarotene) Cream, 0.05% in order to demonstrate bioequivalence and to demonstrate the superiority of the 2 active…
- Trial name
- NCT02160665
- Testing
- Tazarotene Cream, 0.05%, Vehicle, Reference: Tazorac Cream, 0.05%
- Where
- United States
- Volunteers
- 866 people, healthy volunteers welcome
- Sponsor
- G & W Laboratories Inc.
Plaque Psoriasis
Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
This is a multiple-center, randomized, double-blind, placebo-controlled Phase IIb study to evaluate the efficacy and safety of AK101, an anti-IL-12/23 p40 antibody, when administered subcutaneously, in subjects with…
- Trial name
- NCT04173637
- Testing
- AK101
- Where
- 2 sites in China
- Volunteers
- 330 people
- Sponsor
- Akeso
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.